Skip to main content Back to Top
Advertisement

Overcoming Barriers to Sodium Glucose Cotransporter-2 Inhibitor Adoption

May 1, 2025


ABOUT THIS PODCAST

Sodium Glucose Cotransporter-2 Inhibitors (SGLT2) have demonstrated improvement in patient outcomes across several disease states including patients with type 2 diabetes, heart failure and chronic kidney disease.  Despite guideline recommendations for the use of these agents in each of these disease states, utilization of SGLT2 remains relatively low. This podcast discusses some of the barriers to utilization of SGLT2 and strategies to increase uptake of this therapy among patients with diabetes, heart failure and chronic kidney disease. 

SPEAKERS

  • Sin Yan Yeung, PharmD BCCCP
    Clinical Pharmacy Specialist, MICU, University of Maryland Medical Center
  • Rebecca Maxson, PharmD, BCPS, FCCP
    Associate Clinical Professor, Auburn University
    Ambulatory Nephrology Pharmacist, University of Alabama Birmingham Hospital, Kirklin Clinic
  • Richard Roveili, PharmD, BCCP
    Clinical Pharmacy Specialist, Cardiology, University of Maryland Medical Center
  • Orly Vardeny, PharmD, MS
    Professor of Medicine, Minneapolis VA Center for Care Delivery and Outcomes Research, University of Minnesota

LISTEN ON


iTunes      Google            Spotify      TuneIn      iHeart Radio


The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Clinical Conversations